Attached files

file filename
EX-99.1 - PRESS RELEASE ISSUED JANUARY 6, 2012 - UROLOGIX INCurologix120085_ex99-1.htm

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (date of earliest event reported):  January 6, 2012

 

 

Urologix, Inc.

(Exact name of Registrant as Specified in its Charter)

 

Minnesota

(State Or Other Jurisdiction Of Incorporation)

 

000-28414 41-1697237
(Commission File Number) (I.R.S. Employer Identification No.)
   
14405 21st Avenue North
Minneapolis, MN
55447
(Address Of Principal Executive Offices) (Zip Code)

 

(763) 475-1400

Registrant’s Telephone Number, Including Area Code

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 
 

 

 

Items under Sections 1, 2 and 4 through 7 are not applicable and are therefore omitted.

 

ITEM 3.01  NOTICE OF DELISTING OR FAILURE TO SATISFY A CONTINUED LISTING RULE OR STANDARD; TRANSFER OF LISTING.
   
ITEM 8.01 OTHER EVENTS.

 

On January 6, 2012, Urologix, Inc. (the “Company”) received a letter from The Nasdaq Stock Market stating that, because the bid price of the Company’s common stock was at least $1.00 per share for 10 consecutive business days, the Company has regained compliance with Listing Rule 5550(a)(2).

 

On January 6, 2012, the Company issued a press release, attached hereto as Exhibit 99.1, relating to its compliance with the requirements for continued listing on The Nasdaq Capital Market.

 

ITEM 9.01  FINANCIAL STATEMENTS AND EXHIBITS

 

Exhibit No.   Description
99.1   Press Release issued by Urologix, Inc. on January 6, 2012.

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  UROLOGIX, INC.
     
  By: /s/ Brian J. Smrdel
    Brian J. Smrdel
Chief Financial Officer

 

Date:  January 9, 2012